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Abstract 
 
Oncogenic BRAF and NRAS mutations drive human melanoma initiation. We used transgenic zebrafish 
to model NRAS mutant melanoma and the rapid tumor onset allowed us to study candidate tumor 
suppressors. We identified P38α-MAPK14 as a potential tumor suppressor in The Cancer Genome Atlas 
melanoma cohort of NRAS mutant melanomas, and overexpression significantly increased the time to 
tumor onset in transgenic zebrafish with NRAS-driven melanoma. Pharmacological activation of P38α-
MAPK14 using anisomycin reduced in vitro viability of melanoma cultures, which we confirmed by 
stable overexpression of p38α. We observed that the viability of MEK-inhibitor resistant melanoma cells 
could be reduced by combined treatment of anisomycin and MEK-inhibition. Our study demonstrates 
that activating the p38α-MAPK14 pathway in the presence of oncogenic NRAS abrogates melanoma in 





The significance of our study is in the accountability of NRAS mutations in melanoma. We demonstrate 
here that activation of p38α-MAPK14 pathway can abrogate NRAS mutant melanoma which is contrary 
to the previously published role of p38α-MAPK14 pathway in BRAF mutant melanoma. These results 
implicate that BRAF and NRAS mutant melanoma may not be identical biologically. We also 
demonstrate the translational benefit of our study by using a small molecule compound-anisomycin 




Melanoma arises from the acquisition of several sequential oncogenic events (Shain et al., 2016). The two most 1 
frequently mutated oncogenes in melanoma are BRAF and NRAS, in which activating mutations lead to constitutive 2 
signaling of the mitogen-activated protein kinase (MAPK) pathway and thereby enhance tumor growth and promote 3 
disease progression (Akbani et al., 2015; Davies et al., 2002; Platz, Egyhazi, Ringborg, & Hansson, 2008). Although 4 
several therapeutic options exist for melanoma, novel strategies targeting NRAS mutations are still at an exploratory 5 
stage. During development, highly conserved cues regulate pigment cell fate, mainly through the expression of the 6 
microphthalmia-associated transcription factor (MITF) (Widlund & Fisher, 2003). Melanoma models that express the 7 
activated human oncogenes NRASQ61K or BRAFV600E under control of the mitfa promoter in zebrafish melanocytes have 8 
been powerful models to study the basic mechanisms of tumorigenesis. Previously, zebrafish have been used to generate 9 
in vivo models to simulate human naevi and melanoma (C. J. Ceol et al., 2011; Dovey, White, & Zon, 2009; Kaufman 10 
et al., 2016; Patton et al., 2005). Similar to (McConnell et al., 2019), we followed the approach of generating a rapid, 11 
transient mitfa promoter driven NRASQ61K zebrafish melanoma model in mitfaw2;tp53zdf1 double mutants using the 12 
minicoopR vector and Tol2 transgenesis system. 13 
To identify suppressors of NRAS-driven melanoma in humans, we analyzed The Cancer Genome Atlas, which revealed 14 
that P38α-MAPK14 is often gained in human melanomas with NRAS oncogenic mutations and loss-of-function p53. 15 
These patients survive longer than their peers do. P38α-MAPK14 overexpression in vivo significantly delayed the onset 16 
of NRASQ61K driven melanoma, confirming its role as a tumor suppressor in this genetic background. We reproduced 17 
these results in vitro demonstrating that stable overexpression of p38α-MAPK14, or pharmacological activation of p38α-18 
MAPK14, was tumor suppressive in NRASQ61K mutant patient-derived melanoma cultures.  19 
Methods 20 
In vivo experiments 21 
Gateway entry clone pENTR5-mitf was created by PCR amplifying full length open reading frame using M24 Nac>Nac 22 
(Dorsky, Raible, & Moon, 2000) (gift from Randall Moon, Addgene plasmid # 17174) and ligated to pENTR5-TOPO 23 
activated vector (Invitrogen) according to manufacturer’s instructions (Khosravi-Far et al., 1996). Gateway middle entry 24 
clones pmiddle-NRASQ61K and pmiddle-MAPK14 was created by PCR amplifying full length open reading frame using 25 
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pBabe N-Ras 61K (gift from Channing Der, Addgene plasmid # 12543) and pDONR223-MAPK14 (gift from William 26 
Hahn & David Root, Addgene plasmid # 23865) and ligated to pENTR/D-TOPO TA (Invitrogen) using manufacturer’s 27 
instructions (Hao et al., 2007; Johannessen et al., 2010). The pENTR5-mCherry and the MiniCoopR destination vector 28 
were gifts from Dr. Alexa Burger and Dr. Craig Ceol respectively. Individual MiniCoopR clones were created by 29 
ligating the entry vector containing mitf promoter, either of the middle entry vectors and pENTR5-mCherry  to the 30 
minicoopR destination vector using LR clonase under standard conditions (Invitrogen). Tol2mRNA transposase was 31 
created using the SP-6 primer and the PCS-TP vector (Kawakami et al., 2004) with the mMESSAGEmMachine kit 32 
(Ambion Inc) according to manufacturer’s instructions. The pENTR5-mCherry was only used for its compatibility to 33 
fulfill the LR reaction. The middle entry clones containing the genes of interest were cloned with a stop codon at the 34 
end to prevent any m-Cherry expression. This had been done in order to avoid any abnormal expression of our genes of 35 
interest. Varying concentrations (60-100 ng/µl) of individual minicoopR vector along with 25 ng/µl of Tol2 mRNA 36 
transposase was microinjected into mitfaw2;tp53zdf1 double mutant embryos at one cell stage. At larval stages post 37 
injection, embryos with rescued melanocytes were chosen for further assessment and scored weekly for presence of 38 
visible tumors. Zebrafish maintenance and genotyping protocols have been described in details in supplementary 39 
methods. 40 
TCGA Methods 41 
The results shown here are in whole or part based upon data generated by the TCGA Research Network: 42 
https://www.cancer.gov/tcga. No new genetic datasets were made. Publicly available SKCM TCGA data were 43 
downloaded with the TCGAbiolinks package (Cava et al., 2017). Patients with an oncogenic NRAS mutation, G12 or 44 
Q61, and with a p53 non-synonymous mutation and/or copy number loss were selected for further analysis. This cohort 45 
of patients was segregated into two groups: patients surviving less than 1 year, or patients surviving more than 1 year. 46 
The copy number GISTIC scores between these two groups were compared using a chi-squared test. 47 
Immunohistochemistry  48 
Zebrafish were euthanized and stored in 10 % formalin. Zebrafish were dissected and decalcified in 0.5 M EDTA, 49 
embedded in paraffin block and cut into 5 µm thick sections. The sections were then deparaffinized, rehydrated in 50 
decreasing concentrations of alcohol (99 %, 90 %, 70 %), bleached (3 %H2O2 and 1 %KOH) and antigen retrieved. 0.1 51 
M citric acid (8.2 mM sodium citrate, pH 6) was used for mitf, Melan-A, pH3 and Sox10 while Tris-EDTA buffer (10 52 
mM Tris, 1 mM EDTA, 0.05 % Tween 20, pH 9) was used for p38α and phospho-p38α. Serum free protein blocking 53 
(DAKO) was carried out for 30 minutes at room temperature and incubated with primary antibody overnight at 4 oC.  54 
After removal of primary antibody and washing with TBS buffer the slides were incubated with HRP rabbit/mouse 55 
secondary antibody and incubated for 30 minutes at room temperature followed by washing with TBS buffer. For 56 
visualization DAB chromogen:DAB substrate (DAKO 1:50) was used to reveal the HRP at room temperature followed 57 
by washing with water. The slides were then counter stained with haematoxylin for 4 minutes followed by washing and 58 
rinsing with water and acidic alcohol, blued up lithium chloride and finally dehydrating with increasing concentrations 59 
of alcohol (70 %, 90 %, 99 %) and washing in xylene. The slides were mounted using DPX mounting media and left to 60 
dry. Primary antibodies used were Mitf (Abcam 1:1500), Sox10 (Abcam 1:2500), Melan-A (DAKO 1:50), phospho-61 
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Histone 3 (Cell Signaling 1:200), p38α (Cell Signaling 1:800) and phospho-p38α (Cell Signaling 1:1000). Sections were 62 
imaged using Hamamatsu Nanozoomer XR slide scanner. 63 
Cell lines and culture conditions 64 
The patient-derived melanoma cell lines were provided by Melanoma Biobank, University Hospital Zurich, which were 65 
derived according to previously described methods (Raaijmakers et al. 2015) . All melanoma cell lines were cultured in 66 
RPMI1640 medium supplemented with 5 % fetal bovine serum and 2 mM L-glutamine and 50 mg/ml of Normocin 67 
(invivoGen). HEK293T cells were cultured in DMEM medium supplemented with 5 % fetal bovine serum and 2 mM 68 
L-glutamine. All cell lines were maintained at 37 oC in a humidified 5 % CO2 atmosphere. Anisomycin and SP600125 69 
was obtained from Cell Signaling. P38  inhibitor SB203580 was obtained from Selleckchem. MEK inhibitor trametinib 70 
was obtained from Novartis, Zurich. 71 
Cell Viability assay 72 
The growth inhibitory effect was tested under four different conditions- treatment with anisomycin, treatment with 73 
SB203580, treatment with MEK inhibitor-trametinib only, treatment with combination of anisomycin and trametinib. 74 
DMSO was used as the vehicle control for all the experiments. The cells were seeded at a density of 2 x 103 cells/well 75 
in a 96 well plate. 24 hours post seeding they were treated with either of the 4 conditions. After 72 hours of incubation 76 
the treated medium was aspirated and 100 µL of 1x Resazurin was added and incubated until color change was observed 77 
in the wells. Absorbance was measured at 490 nm using a microplate reader (Tecan, infinite M200Pro). Each experiment 78 
was performed with at least three biological replicates and repeated at least three times. IC50 calculations were made 79 
using GraphPad Prism and the synergy calculations were made using Synergyfinder. 80 
DNA synthesis inhibition assay 81 
The ability of anisomycin or SB203580 to inhibit cell proliferation was determined using BrdU colorimetric assay 82 
(Roche). The quantification of cell proliferation is based on the measurement of BrdU incorporation during DNA 83 
synthesis in proliferating cells. The cells were seeded at a density of 2 x 103 cells/well in a 96 well plate. 24 hours post 84 
seeding they were treated with anisomycin or SB203580. 72 hours post-treatment BrdU labelling solution, anti BrdU 85 
POD solution, washing solution and substrate solution was added according to manufacturer’s instructions (Cell 86 
proliferation ELISA, BrdU colorimetric, Roche). Absorbance was measured at 370 nm using a plate reader (Tecan, 87 
infinite M200Pro). Each experiment was performed with three biological replicates and repeated at least three times.  88 
P38α and phospho-p38α activation and inhibition 89 
Cells were lysed with radioimmuno precipitation assay (RIPA) buffer (150 mM NaCl,15 mM MgCl2,1 mM EDTA, 50 90 
mM HEPES, 10 % glycerol, 1 % triton-X100, 1 tablet/mL each of phosphatase inhibitor and protease inhibitor) on ice 91 
for 30 minutes and 20 µg of protein were analyzed using standard western blotting. Protein quantification was done 92 
using standard Bradford assay. Cell lysates were collected 30 minutes post 0.1 µM/100 µM anisomycin treatment or 2 93 
hours post 10 µM SB203580/SP600125 or 30 minutes pre-treatment with anisomycin followed by 2 hours treatment 94 
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with SB203580/SP600125. P38α, phospho-p38α, total JNK, phospho-JNK, total ERK, phospho-ERK, total MEK and 95 
phospho-MEK (Cell Signaling) were used at 1:1000 dilution. Anti-hsp90 (Cell Signaling) was used as loading control 96 
at 1:1000 dilution. Following the probing of membrane for phospho-antibodies, they were stripped using stripping buffer 97 
(15 g glycine, 1 g SDS, 10 mL Tween20 in 1 L dd.H20) followed by blocking and primary antibody incubation overnight. 98 
All membranes were probed for 60 minutes at room temperature with secondary anti-rabbit antibody (Cell Signaling) 99 
at 1:2000 dilution. The visualization was performed using ECL chemifluorescent reagent (Invitrogen) or ECL-western 100 
bright Sirius/Quantum (Advantas).  101 
Colony formation assay 102 
Cells were seeded in 12 well plate at a density of 5 x 102, 1 x 103, 2 x 103 with 4 replicates and incubated at 37 oC. RPMI 103 
supplemented medium was re-freshed every 72 hours. The cell lines were incubated until colonies appeared within 10-104 
15 days. For staining, 1 ml/well crystal violet (0.5 % w/v) dye was added and incubated for 20 minutes at room 105 
temperature on a shaker. Next, the plates were inverted and washed gently under running tap water. The plates were 106 
inverted and dried over night at room temperature. The plates were measured using EPSON scanner and analyzed using 107 
the Image J plugin-colony area (Guzman, Bagga, Kaur, Westermarck, & Abankwa, 2014). 108 
Production of stably transduced cell lines overexpressing p38α-MAPK14 109 
 110 
To create the vector containing p38α-MAPK14 driven by CMV promoter, the p38α-MAPK14 full length open reading 111 
frame was PCR amplified using primers F5’AGGGAGACCCAAGCTTGGTACCGGCACC3’ and 112 
R5’TCAGGACTCCATCTCTTCTTGGTC3’. Addgene vector 62148 (Albers et al., 2015) with CMV promoter driving 113 
mCherry was used to restriction digest mCherry sequence with KpnI and SalI to create an open vector in order to replace 114 
the mCherry sequence with p38α sequence. Next, the PCR product with full length p38α sequence was ligated to open 115 
vector with CMV promoter using HiFi DNA Master Mix under standard conditions (NEB). This vector containing p38α-116 
MAPK14 driven by CMV promoter was embedded in pMuLE Lenti Dest eGFP  backbone co-expressing green 117 
fluorescent protein (GFP) (gift from Ian Frew, Addgene plasmid #62175) (Albers et al., 2015) using  entry vector pMuLE 118 
ENTR MCS L5-L2 (gift from Ian Frew, Addgene plasmid #62085) in a site directed LR gateway reaction (Invitrogen). 119 
LR site directed gateway cloning was used in the same way to create mock vector expressing only GFP. Addgene vector 120 
62084 (Albers et al., 2015) (gift from Ian Frew, Addgene plasmid #62084) was used instead of p38α entry vector as 121 
middle entry clone. Entry vectors 62084 and 62085 were re-combined with destination vector 62175 to create final 122 
expression vector as described above.  The expression vector with p38α-MAPK14/mock-GFP, the packaging plasmid 123 
psPAX2 (Trono) and the envelope plasmid pMD2.G (Trono) were co-transfected with polyethylenimine (Polysciences) 124 
on HEK293T cells. 48 hours post transfection media containing lentiviral particles were added to melanoma cells in a 125 
1:1 ratio with RPMI. The transduced cells were FACS-sorted for GFP before expanding. 126 
Annexin-V/PI staining 127 
 128 
Cell death to measure apoptosis was assayed using Annexin-V/PI kit (Invitrogen). Cells were seeded up to confluency 129 
in six well plates. On the day of treatment, the monolayer was collected, the cells were washed once with PBS and 130 
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trypsinized. All supernatants including live and dead cells were collected before centrifuging for 5 minutes at 1500 rpm. 131 
Cells were re-suspended in 150 µL 1x binding buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM CaCl2, pH 7.4) in 132 
concentration of 1 x 106 cells/mL. 5 µL of PI/Annexin-V was added and incubated at room temperature in the dark for 133 
20 minutes. Samples were transferred to ice and analyzed immediately on BD FACS AriaII. FloJo software was used 134 
for analysis. 135 
 136 
Statistical Analysis and blinding approach 137 
 138 
Results of in vitro experiments are presented as mean ± standard deviation or mean ± standard error representation of 139 
three independent experiments. Student t-test was used to compare continuous variables. Chi-squared test was used to 140 
measure categorical data, specifically to account for the different stages of apoptosis upon treatment with anisomycin 141 
in Figure 4. Median time to tumor formation was analyzed using Log rank test and Kaplan Meier method. P-value of 142 
less than 0.05 was considered statistically significant. 143 
A partial blinding approach was followed for some of the experiments. The injection of plasmids, staining and analyzing 144 
of tissue section was performed by 2 people at 2 different time points. The tubes used to store the plasmids before 145 
injection and the slides for IHC were labelled with numbers only, eliminating gene names (such as NRAS or p38). One 146 
person in both the experiments was blinded.  147 
Results 148 
 149 
Tumor suppressive function of p38α in NRAS driven transgenic zebrafish melanoma 150 
 151 
In order to study the oncogenic role of human NRASQ61K, we produced a transgenic model in zebrafish using the Tol-2 152 
miniCoopR vector (Craig J. Ceol et al., 2011). We generated individual clones of human NRASQ61K Tol-2 vectors and 153 
injected them into single cell mitfaw2;tp53zdf1 double loss-of-function mutants. In this system, candidate genes such as 154 
NRASQ61K are physically coupled to the mitfa rescuing minigene. They are therefore expressed in rescued melanocytes, 155 
some of which will transform and develop into tumors (Iyengar, Houvras, & Ceol, 2012). We then monitored those fish 156 
with rescued melanocytes  for one year. We stained the tumor sections derived from euthanized, transgenic fish which 157 
were positive for the proliferation marker pH3 and classic melanoma markers such as Melan-A, MITF, and Sox10 158 
(Figure 1A). Due to the very early onset of melanoma (i.e., 37 days) in the NRASQ61K transgenic fish, they could not be 159 
mated. These data suggest that the NRASQ61K oncogene generates aggressive melanoma tumors in zebrafish. Due to the 160 
histological similarity of zebrafish melanoma to human nodular/cutaneous melanoma and the rapid melanoma onset, 161 
we considered mitfa driven NRASQ61K transgenic zebrafish to be an efficient tool for further mechanistic experiments 162 
(Patton et al., 2005) (Ceol, Houvras, White, & Zon, 2008). 163 
 164 
Given the high medical need for therapies in NRAS-mutated melanomas, we analyzed the publicly available TCGA 165 
(https://www.cancer.gov/tcga) cohort of p53-mutated NRAS-mutant melanoma patients for potential tumor-suppressor 166 
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genes. In order to identify copy number variants and differentially expressed genes, we classified the cohort based on 167 
survival time. We compared the genetic profiles of  long survivors with (overall survival) O.S >1 year and short survivors 168 
with O.S <1 year (Figure 1B). There were several significant genes with copy number differences between these groups. 169 
To identify potential genes that could provide a protective role when overexpressed in NRAS-mutated melanomas, we 170 
considered only copy number gains that might suppress the rapid tumor onset observed in NRASQ61K transgenic 171 
zebrafish. Furthermore, to ensure functional disease relevance, candidate gene selection was based on highly conserved 172 
genes, particulary those with ≥80 % sequence similarity to the Danio rerio genome (Supplementary Figure 2). P38α 173 
(i.e., MAPK14) was the most relevant cancer associated gene gained in long survivors and most importantly even lost 174 
in some short survivors (Figure 1C, p=0.037). P38 mitogen-activated protein kinases are a class of mitogen-activated 175 
protein kinases that are responsive to stress stimuli, such as heat and osmotic shock, cytokines, and UV irradiation and 176 
they are involved in cell differentiation, autophagy, and apoptosis. Four p38 MAP kinases, p38α (MAPK14), β 177 
(MAPK11), γ (MAPK12/ERK6), and δ (MAPK13/SAPK4), have been identified, and their functions in cancer remain 178 
elusive (Meng & Wu, 2013). The p38 pathway has been most frequently associated with a tumor suppressor function 179 
by negatively regulating cell survival and proliferation (Han & Sun, 2007). Although it has been suggested that 180 
modulating p38 or its downstream targets, PODXL and DEL-1 can serve as candidate therapeutics in melanoma (J. 181 
Wenzina et al., 2020), the role of p38α in melanoma is unclear and needs further investigation. We therefore 182 
hypothesized that p38α was a tumor suppressor in NRAS mutant melanoma. To test this, we engineered the miniCoopR 183 
vector to overexpress p38α and injected it into mitfaw2;tp53zdf1 double mutant embryos along with the miniCoopR vector 184 
overexpressing NRASQ61K. We then screened the embryos for melanocytic rescue in larval stages and then monitored 185 
them for tumor development for one year. The onset of melanoma in NRASQ61K transgenic zebrafish occurred very 186 
early, by 37 days, demonstrating the aggressiveness of NRAS mutant melanoma. Interestingly, 30.7 % of fish developed 187 
tumors in Tg(mitfa:p38α);Tg(mitfa:NRASQ61K);mitfaw2;tp53zdf1  in comparison to 54.8 % in 188 
Tg(mitfa:NRASQ61K);mitfaw2;tp53zdf1 (Figure 1D). Of the 30.7 % fish that developed tumors in 189 
Tg(mitfa:p38α);Tg(mitfa:NRASQ61K);mitfaw2;tp53zdf1, the first tumor development was at 71 days (Figure 1D). We also 190 
confirmed the expression of p38α and phospho-p38α   by immunohistochemistry on tumor/skin section excised from 191 
the euthanized, transgenic animals (Figure 1E-G). Tg(mitfa:NRASQ61K);mitfaw2;tp53zdf1 had negligible amounts of p38α 192 
and phospho-p38α in the tumor sections (Figure 1E). Tg(mitfa:p38α);mitfaw2;tp53zdf1 did not develop any tumors nor 193 
did they show any abnormal disease related behavior (Figure 1F). Since these fish had melanocytic expression of p38α, 194 
immunohistochemistry revealed positive expression of p38α and phospho-p38α only in the epidermal sections of skin 195 
that consisted of melanocytes (Figure 1F).Tumor sections from Tg(mitfa:p38α);Tg(mitfa:NRASQ61K);mitfaw2;tp53zdf1 had 196 
dramatically high levels of p38α and phospho-p38α (Figure 1G). Therefore, overexpression of p38α in zebrafish 197 
melanocytes bearing mitfa-restricted NRASQ61K had a survival benefit as measured by tumor free survival time by about 198 
50 %. These combined data suggest that p38α is a tumor suppressor in the context of NRASQ61K zebrafish melanoma.  199 
 200 
Overexpression of p38α induces tumor suppressive effects in vitro  201 
In order to investigate if the observations made in vivo could be reproduced in vitro, we chose 6 patient-derived human 202 
melanoma cell cultures derived from tumors from different metastatic sites (i.e., 122102, 130107, 140805, 130227, 203 
130429, and 160915 detailed in supplementary figure 1). To elucidate the role of p38α as a tumor suppressor, we stably 204 
transfected two patient-derived melanoma cell lines (130429 and 160915) to overexpress p38α. In addition, we also 205 
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stably transfected the same cell lines to overexpress CMV-driven EGFP, which were labelled as EV (empty 206 
vector)_GFP_130429/160915. The cell lines that were transfected to overexpress p38α were labelled as 207 
p38α_GFP_130429/160915. The cell lines were probed for p38α and phospho-p38α with specific antibodies to confirm 208 
protein expression of p38α and phopsho-p38α with and without low doses of the p38 activator anisomycin (Figure 2A-209 
B). To directly assess the role of p38α, on cell survival, we used resazurin assay to compare cell viability, which was 210 
significantly decreased in comparison to EV_GFP_130429/160915 (Figure 2C-D). Next, to monitor long-term effects 211 
of stable over-expression of p38α, we tested the ability of the transfected cells to form colonies using the colony 212 
formation assay. Consistent with the viability results, we observed reduced clonogenicity in the p38α transfected cell 213 
lines 130429 and 160915 compared to  EV_GFP_130429/160915. The clonogenicity was measured by calculating the 214 
percentage of area covered by colonies formed (Figure 2E-F). The reduced cell viability and reduced clonogenicity 215 
could be attributed to either a reduction in cell proliferation or some form of cell death. We therefore performed an 216 
Annexin-V PI (Propidium iodide) death assay to check for apoptosis. Indeed, we found a significantly large proportion 217 
of early, late, and total apoptotic cells in the p38α overexpressing cell lines 130429 and 160915 (Figure 2G-H). In 218 
summary, tumor suppressive functions, such as reduced clonogenicity and viability, appeared to be apoptosis-mediated 219 
in the stably transfected p38-α overexpressing cell lines 130429/160915. Overall, these data suggest an inhibitory effect 220 
of overexpression of p38α on NRAS mutant melanoma cells. 221 
Pharmacological activation of p38α by anisomycin leads to tumor suppressive phenotypes in vitro 222 
 223 
Our observations provided evidence that upregulation of the p38α-MAPK14 pathway could contribute to tumor 224 
suppressive functions. For this reason, we used anisomycin, which activates the p38α-MAPK14 pathway by 225 
phosphorylation of p38 (Hazzalin, Le Panse, Cano, & Mahadevan, 1998), while the pharmacological inhibitor 226 
SB203580 blocks the phosphorylation of p38 (Ana Cuenda et al., 1995). The levels of phospho-p38α were elevated 227 
when the six cell lines were treated with anisomycin, which could be reduced by treating the cells with the inhibitor 228 
SB203580 (Figure 3A, western blots). Therefore, the p38α-MAPK14 pathway could be modulated with the p38α 229 
activator anisomycin and the inhibitor SB203580 in all the patient-derived melanoma cell cultures used in this study. 230 
To examine the functional consequences on p38α-mediated cell survival, we determined cell viability using resazurin 231 
assays in the presence of anisomycin or SB203580. Treatment of melanoma cells with anisomycin resulted in reduced 232 
cell viability in a dose dependent manner as measured by the IC50 (half maximal inhibitory concentration) of all cell 233 
lines (Figure 3A). However, cell viability was not affected by SB203580 even up to a concentration of 1 µM. The IC50 234 
of cells treated with anisomycin was at a low toxicity range between 0.2-0.3 µM while most cells had an IC50 ≥5 µM 235 
when treated with SB203580 (Figure 3A). Resazurin results were validated using BrdU colorimetric assays that measure 236 
the DNA synthesis of a cell. When the cells were stimulated with anisomycin, the incorporation of BrdU was dose 237 
dependently reduced in comparison to stimulation by SB203580, suggesting reduction of DNA synthesis under 238 
anisomycin treatment as measured by the IC50 values (Figure 3B). Overall, there was a significant change in cell 239 
viability and proliferation upon treatment with anisomycin as measured by both, resazurin and BrdU assays. These data 240 
show that cell viability and proliferation could be limited by activation of p38α suggesting a tumor suppressive role of 241 
p38α in NRAS mutant melanoma cells.  242 
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Activation of p38α by anisomycin mimics stable overexpression of p38α and re-sensitizes MEK inhibitor 243 
resistant cells to cell death 244 
 245 
So far, our results clearly suggested that up-regulation of p38α in NRAS mutant cells had tumor suppressive effects. We 246 
next wanted to test whether the reduced melanoma cell viability upon anisomycin treatment was also due to an increase 247 
in apoptosis. For this reason, we performed Annexin-V PI assays after 72 hours of treatment with 0.1 µM anisomycin. 248 
Consistent with the results obtained earlier, treatment with anisomycin induced a significantly higher rate of apoptosis 249 
in 122102, 130429 and 160915 compared to untreated cells (Figure 4A). Although not significant, 130227 cells had a 250 
10 % increase in overall apoptosis when treated with anisomycin while 140805 did not have any significant change in 251 
apoptosis. Treated 130107 cells had a very high degree of apoptosis (>90 %) even without treatment, possibly due to 252 
their sensitivity to the staining dyes and incubation times for a FACS read-out. An account of early, late, and total 253 
apoptosis indicated that the late apoptosis population in anisomycin-treated cells is particularly high (Figure 4A). Taken, 254 
together these results show that tumor suppressive functions can be achieved by pharmacological activation of phospho-255 
p38α with anisomycin and can be used as an alternative to stable transfection of p38α overexpression. More importantly, 256 
these results demonstrate that the consequence of high p38α in NRAS mutant melanoma cells either by genetically 257 
modifying cells to overexpress p38α or by using anisomycin is mostly apoptosis-mediated cell death. 258 
 259 
In order to evaluate the use of anisomycin as a therapeutic agent to target melanoma cells, we compared its effectiveness 260 
to that of the commonly used MEK inhibitor trametinib. Cell viability was compared by using IC50 values attained after 261 
resazurin assays. All patient-derived melanoma cells collected at the University of Zurich Biobank are tested for drug 262 
sensitivity after expansion of cells in vitro in addition to comparing patient responses. Drug sensitive cell lines have 263 
IC50 of ≤0.1µM. All cell lines used in this study were considered to be drug resistant except for 130429. Indeed, from 264 
our experiments we observed that 130429 was MEKi sensitive and had the lowest IC50 value with trametinib treatment 265 
(Figure 4B, right). In contrast, all cell lines responded with reduced dose-response inhibition when treated with 266 
anisomycin as seen by a sigmoidal curve (Figure 4B, left). IC50 was in the range of 0.02-1µM in case of anisomycin 267 
treatment. Interestingly, the IC50 of the trametinib-sensitive cells 130429 was 0.04 µM compared to 0.02 µM with 268 
anisomycin. Therefore, as a single agent to reduce cell viability, anisomycin works more effectively than trametinib in 269 
all NRAS mutant melanoma cell lines used in this study. Lastly, to re-sensitize trametinib resistant melanoma cells, we 270 
co-treated the cells with anisomycin and trametinib with a concentration matrix ranging from 0.1-1000 nM. A synergy 271 
score was assigned to each value and is indicated by red color. A synergistic value was obtained for five cell lines when 272 
co-treated with anisomycin and trametinib in a low cytotoxicity range of 0.1-10 nM as indicated by red synergy zones 273 
(Figure 4C). Cell line 140805 did not show synergy. The dose-response matrix for each cell line can be found in 274 
Supplementary Figure 3. Therefore, anisomycin, when used either as a single agent or in combination with trametinib, 275 
resulted in a reduction of cell viability in most of the NRAS melanoma cell lines tested in this study.  Thus, low dose 276 
anisomycin treatment in NRAS mutant melanoma cells sensitizes them to MEK-inhibition treatment. 277 




To understand the mechanism of action of the short-term effects of low and high dose anisomycin, we collected cell 280 
lysates 30 minutes post treatment with 0.1 µM and 100 µM anisomycin and probed for MAPK pathway proteins 281 
phospho-JNK, phospho-ERK, and phospho-MEK along with phospho-p38α. We found a positive correlation between 282 
phospho-p38α and phospho-JNK under both low and high dose anisomycin for five cell lines (Figure 5). (The NRAS 283 
mutation was lost in 140805 and this cell line was excluded from hereon). All cells had high phospho-p38α and high 284 
phospho-JNK with only a partial increase of phospho-ERK under low and high anisomycin treatment. The levels of 285 
phospho-MEK remained unchanged. The total protein levels of p38α, JNK, ERK and MEK remained unchanged (Figure 286 
5). These results prompted us to inquire if phospho-p38α protein levels could be affected by JNK inhibition.  Indeed, 287 
anisomycin induced phospho-p38α protein expression could be suppressed not only by the p38α inhibitor SB203580 288 
but also by the JNK inhibitor SP600125 in 122102, 130227 and 130429 (Figure 6). However, in 130107 and 160915, 289 
the addition of SP600125 in combination with anisomycin increased the phospho-p38 protein levels. It should be kept 290 
in mind that 130107 and 160915 had elevated levels of phospho-JNK when treated with anisomycin indicating that 291 
activated states of p38α can bypass JNK inhibition and that JNK inhibition is not enough to restore the inactivated state 292 
of p38α. This also suggests that once activated, p38α follows different pathways and feedback loops. These results 293 
strongly suggest a partial co-activation of both phospho-JNK and phospho-p38α upon stimulation by anisomycin. 294 




Our results demonstrate that NRAS mutations with p53 loss cause rapid onset of melanoma in zebrafish. The 299 
hyperpigmentation and accelerated tumor onset is comparable to observations made by (McConnell et al., 2019) in their 300 
mcr:NRASQ61R transgenic line. Similar results were previously reported in eGFP:NRAS transgenic zebrafish (Dovey et 301 
al., 2009). Fish with the NRASQ61K transgene Tg(mitfa:NRASQ61K);mitfaw2;tp53zdf1 developed rapid melanoma, making 302 
it a suitable model to pursue the identification of tumor suppressors. The current standard of care for metastatic patients 303 
with NRAS driver mutations are immune-based therapies as first-line treatments, then cytotoxic chemotherapy such as 304 
carboplatin/paclitaxel (C/P), dacarbazine (DTIC) or temozolomide (TMZ) as a second-line treatment (Boespflug, 305 
Caramel, Dalle, & Thomas, 2017). Since there is no FDA approved targeted therapy for NRAS mutant melanoma 306 
patients, new studies are needed to investigate the role of tumor suppressors or oncogenes for the development of 307 
druggable targets in the MAPK pathway. This, combined with the establishment of a rapid melanoma model harboring 308 
NRAS mutations, paved the way for this study to be focused on finding candidate genes that might be tumor suppressors 309 
in NRAS melanoma. We used the TCGA cohort consisting of NRAS mutant melanoma patients with p53 null alleles to 310 
match the background mutations in our zebrafish model. We stratified the cohort based on their survival and identified 311 
a candidate tumor suppressor gene, p38α-MAPK14. The role of p38α has been implicated in liver, prostate, breast, 312 
bladder, lung, thyroid, head and neck squamous cell carcinomas (Demuth et al., 2007; Elenitoba-Johnson et al., 2003; 313 
Esteva et al., 2004; Greenberg et al., 2002; Iyoda et al., 2003; Junttila et al., 2007; Khandrika et al., 2009; Koul, Pal, & 314 
Koul, 2013; Kumar et al., 2010; Park et al., 2003; Pomerance, Quillard, Chantoux, Young, & Blondeau, 2006; Tsai, 315 
Shiah, Lin, Wu, & Kuo, 2003). Mammalian p38 mitogen-activated protein kinases (MAPKs) are activated by a wide 316 
range of cellular stresses as well as in response to inflammatory cytokines (A. Cuenda & Rousseau, 2007).  The p38α-317 
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MAPK14 pathway is involved in a number of physiological functions such as tissue invasion, protection against 318 
apoptotic cell death, unlimited replication potential, de novo angiogenesis and metastasis (Ambrosino & Nebreda, 2001). 319 
Depending on the cell type, p38α-MAPK14 can either induce progression or inhibition at G1/S transition by differential 320 
regulation of specific cyclin levels (cyclin A or D1) as well as by phosphorylation of the retinoblastoma protein (pRb), 321 
which is a hallmark of G1/S progression (Brancho et al., 2003) (Ambrosino & Nebreda, 2001). Overall, p38α plays 322 
various roles in normal conditions, but the role of p38α in solid tumors may be critical for tumor cell survival and 323 
metastasis and the mechanism of action of p38α needs to be further investigated. 324 
Our data suggest that p38α acts as a tumor suppressor in our in vivo zebrafish melanoma model. In mitfaw2;tp53zdf1 325 
double mutants that overexpress both NRASQ61K and p38α, the time to tumor onset was  significantly increased. 326 
Furthermore, our results strongly suggest that p38α retains its tumor suppressive function in vitro. Stable transfection 327 
of human melanoma cells to overexpress p38α induced apoptosis-mediated cell death leading to reduced cell viability 328 
and clonogenicity. We confirmed the tumor suppressive and pro-apoptotic effects of p38α activation upon stable 329 
transfection of p38α that could be phenocopied by pharmacological activation using anisomycin.   330 
High levels of p38α activity act through a negative feedback loop, where ERK signaling prevents tumorigenesis, which 331 
is in line with our findings (Estrada, Dong, & Ossowski, 2009). We also observed reduced phospho-ERK protein levels 332 
24 hours post treatment with anisomycin in the cell lines 122102, 130107, 130227, 130429 and 160915 (Supplementary 333 
Figure 4) suggesting an abrogation of MAPK signaling. p38α plays a dual role as a mediator of cell survival or of cell 334 
death depending on the cell type and stimuli. While the tumor suppressive function of p38α has been described (Bradham 335 
& McClay, 2006; Hickson et al., 2006; Yao et al., 2008), its pro-oncogenic role has also been studied (Wagner & 336 
Nebreda, 2009). The dual role has been attributed to the initial, later, and metastatic stages of cancer (Huret, Dessen, & 337 
Bernheim, 2003). However, our investigation suggests a tumor suppressive role in NRAS driven melanoma. 338 
In support of our model, we also found similar tumor suppressive effects upon the application of anisomycin to 339 
upregulate p38α. Here we showed that anisomycin induced activation of p38α leads to a reduction of cell viability 340 
(resazurin assay) and DNA synthesis in melanoma cells (BrdU assay) and most importantly, low dose anisomycin 341 
induces apoptosis-mediated cell death. Consistently, an earlier study showed that low doses of anisomycin could inhibit 342 
protein synthesis in melanoma cells by up to 30 %, which might result in a shift in the levels of the proteins involved in 343 
apoptosis (Slipicevic et al., 2013). The study also demonstrated that combined treatment of lexatumumab and 344 
anisomycin compared with lexatumumab alone significantly enhanced apoptosis in the melanoma cell lines-FEMX-1 345 
and WM239. 346 
P38α activation can be triggered by a variety of different stimuli and p38α activation is more likely to result in cell 347 
death. How it acts as a tumor suppressor in our model is yet to be determined in detail. Annexin V-PI assays in melanoma 348 
cell lines indicated that p38α overexpressing cells had a higher proportion of late apoptotic cells. P38α linked apoptosis 349 
has been reported to be mediated by caspase dependent and independent events particularly due to high ROS levels, 350 
high ATP, nutrient consumption and oxidative phosphorylation (Dolado et al., 2007; Trempolec et al., 2017). It has been 351 
demonstrated that p38 controls the regulation of checkpoint controls and cell cycle at G0, G1/S, and G2/M transition 352 
(Ambrosino & Nebreda, 2001).   353 
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The necessity of p38α for melanoma cell migration and proliferation was previously described  by others (Estrada et al., 354 
2009). Some studies revealed that inhibition of p38α activity and the subsequent phosphorylation of HSP27 by 355 
MAPKAP-K2 could prevent actin cytoskeleton reorganization necessary for cell migration (Hedges et al., 1999; 356 
Piotrowicz, Hickey, & Levin, 1998; Rousseau, Houle, Landry, & Huot, 1997). Our observations on the tumor sections 357 
obtained from Tg(mitfa:p38α);Tg(mitfa:NRASQ61K);mitfaw2;tp53zdf1 revealed spindle shaped nuclei across the tumor 358 
suggesting a re-organized cytoskeleton in case of p38α expression (Supplementary Figure 5). Another study showed 359 
that changes in (extra-cellular matrix) ECM could lead to recruitment of T-cells (Kaur et al., 2019), a possible 360 
explanation for delay in tumor onset and a rearranged cytoskeleton in zebrafish over-expressing p38α. Matrix 361 
remodeling enzymes such as (matrix metalo-proteases) MMPs also regulate interaction between tumor cells and stroma. 362 
Inhibition of p38α-MAPK14 activity with SB203580 was shown to block MMP-9 expression in phorbol myristate 363 
acetate (PMA)-treated human squamous cell carcinoma (Simon, Goepfert, & Boyd, 1998).  364 
Surprisingly, the positive correlation between high phospho-p38α and high phospho-JNK contrasts with a previously 365 
published study focused on BRAF mutant melanoma (Judith Wenzina et al., 2020). Although our findings suggest a 366 
tumor suppressive role of p38α in NRAS mutated melanoma, it might have a different role in a BRAF mutant 367 
background. The reduction in ERK levels and therefore MAPK signaling (Supplementary Figure4) in high p38α cells 368 
led us to speculate that the normally uncontrolled conversion of GTP in melanoma cells can be limited. GTPase 369 
activating proteins (GAPS) such as neurofibromin, RASA1, RASA2, NF1 are crucial for hydrolysis of GTP to GDP 370 
and indeed we found that p38α and GTPase activating proteins SPRED1, RASA1,RASA2 and NF1 cluster together in 371 
NRAS mutant melanoma cohort (Supplementary Figure 6). Similar observations were made by (J. Tang et al., 2020) 372 
where loss of function mutations in NF1 and RASA2 were found in melanocytes along with gain/change of function 373 
mutation in NRAS.      374 
Our attempt to find out if the patient-derived NRAS mutant melanoma cell lines could be sensitized to the MEK 375 
inhibitor-trametinib led to the identification of synergistic effects on melanoma cell lines when co-treated with 376 
anisomycin and trametinib. Low dose anisomycin as a single agent was more effective at reducing cell viability when 377 
compared to trametinib as indicated by the IC50 values at low cytotoxicity range. In vivo studies have (Z. Tang et al., 378 
2012) shown that anisomycin has low toxicity and no significant side effects at physiological therapeutic doses. 379 
Although the cytotoxicity and long-term side effects of anisomycin need to be investigated, it could be a potential 380 
pharmacological candidate for melanoma patients harboring NRAS mutations. Single-agent MEK-inhibitor therapy has 381 
not been effective as a monotherapy in metastatic melanoma patients and thus, targeting P38α-MAPK14 could be an 382 
alternative.  383 
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Figure Legends 395 
 396 
Figure 1: Identification of candidate tumor suppressor gene and tumor suppressive functions of p38α in 397 
NRASQ61K transgenic zebrafish 398 
A: Histological analysis of tumor sections derived from NRASQ61K transgenic zebrafish stained for H&E, pH3, Melan-399 
A, Mitf and Sox10. Scale bars, 50 µm  B: Segregation of p53 null NRAS mutant TCGA cohort based on overall survival; 400 
short survivors O.S <1 year and long survivors O.S >1 year C: Bar plot showing different proportions of copy number 401 
variants between long and short survivors. Chi-squared test (p=0.037). D: Difference in median onset of tumor between 402 
Tg(mitfa:p38);Tg(mitfa:NRASQ61K);mitfaw2;tp53zdf1 versus Tg(mitfa:NRASQ61K);mitfaw2;tp53zdf1 versus 403 
Tg(mitfa:p38);mitfaw2;tp53zdf1. Log rank test (P=0.0092) E: Histological analysis of tumor sections derived from 404 
Tg(mitfa:NRASQ61K);mitfaw2;tp53zdf1  and stained for H&E, p38α and phospho-p38α  F: Histological analysis of skin 405 
from Tg(mitfa:p38);mitfaw2;tp53zdf1 stained for H&E, p38α and phospho-p38α G: Histological analysis of tumor from 406 
Tg(mitfa:p38);Tg(mitfa:NRASQ61K);mitfaw2;tp53zdf1 stained for H&E, p38α and phospho-p38α. Stainings are 407 
representative sections from three animals except Tg(mitfa:p38);mitfaw2;tp53zdf1. Scale bars, 80 µm. 408 
 409 
Figure 2: Up-regulation of p38α by stable transfection induces apoptosis-mediated cell death resulting in 410 
reduced cell viability and clonogenicity in cell line 130429 and 160915 411 
A-B: Relative protein expression of p38α and phospho-p38α in wt, EV_GFP and p38_GFP in 130429 and 160915 412 
respectively. n≥3 independent experiments C-D: Cell lines 130429 and 160915 stably transfected to express p38α have 413 
significantly reduced cell viability compared to cells stably transfected to express GFP respectively as measured using 414 
Resazurin assay on  day 3 . Each data point in C&D represents an average of 30 values per condition per independent 415 
experiment. Error bars represent standard error of the mean. Statistical tests done using two tailed unpaired student’s t 416 
test and significance values indicated are: p ≤0.05 *, p ≤0.01 **, p ≤0.001 * * * E-F: Significant difference (p <0.001) 417 
in the area covered by colonies in cell line 130429 and 160915 stably expressing p38α compared to cells stably 418 
expressing GFP respectively. Beside are representative pictures of the colonies formed. n ≥3 independent experiments. 419 
Error bars represent standard error of the mean. Statistical tests done using two tailed paired student’s t test and 420 
significance values indicated are: p ≤0.05 *, p ≤0.01 **, p ≤0.001 * * *. G-H: Significantly higher population of cells 421 
undergoing early, late and total apoptosis in cell line 130429 and 160915 stably transfected to express p38α compared 422 
to its mock GFP counterpart respectively. Total apoptosis was calculated as the sum of early, late apoptosis and necrosis. 423 
n ≥3 independent experiments. Error bars represent standard error of the mean. Statistical tests done using two tailed 424 




Figure 3: Activation and inhibition of phospho-p38α by anisomycin and SB203580 respectively and reduction 427 
in cell viability and proliferation upon anisomycin treatment in all cell lines  428 
A: Resazurin assay showing dose-dependent reduction in cell viability with increasing concentrations of anisomycin but 429 
not SB203580 as indicated by the IC50 values (in µM). Each data point represents an average of 3 values per condition 430 
per independent experiment. n ≥3 independent experiments. Error bars represent standard error of the mean. Below: 431 
Western blots showing activation and inhibition of phospho-p38α when stimulated by anisomycin and SB203580 in 432 
respective cell lines. B: BrdU colorimetric assay showing dose dependent reduction in incorporation of BrdU with 433 
increasing concentrations of anisomycin but not SB203580 as indicated by the IC50 values (in µM). Each data point 434 
represents an average of 3 values per condition per independent experiment. n ≥3 independent experiments. Error bars 435 
represent standard error of the mean.   436 
Figure 4: Low dose anisomycin induces apoptosis-mediated cell death in NRAS mutant melanoma cell lines and 437 
shows synergistic effects with MEK inhibitor-trametinib 438 
 439 
A: Annexin V-PI assay demonstrating significantly higher apoptosis rate in anisomycin (0.1 µM) treated 122102, 440 
130429, 160915 compared to untreated cells. Anisomycin (0.1 µM) treated 130227 had 10 % higher apoptosis compared 441 
to untreated cells. Below: Separation of untreated and anisomycin treated cells into early apoptosis Q1, late apoptosis 442 
Q2, necrosis Q3 and live cells Q4. Error bars represent standard error of the mean. n ≥3 independent experiments. 443 
Statistical tests done using Chi-squared test and significance values indicated are: p ≤0.05 *, p ≤0.01 **, p ≤0.001 * * * 444 
B: Resazurin assay upon dose dependent treatment with anisomycin/trametinib. Sensitivity to the drug is measured by 445 
IC50 value in the table below. Each data point represents an average of 3 values per condition per independent 446 
experiment. n ≥3 independent experiments. Error bars represent standard error of the mean. Undetermined IC50 is 447 
indicated by 0.000  C: Synergy plots of 122102, 130107, 130227, 130429 , 140805 and 160915 treated with trametinib 448 
(concentrations on x-axis) and anisomycin (concentrations on y-axis). Red, white and green  indicate synergistic, non- 449 
synergistic and antagonistic effects respectively. Each data point represents an average of 3 values per condition per 450 
independent experiment. n ≥3 independent experiments.  451 
Figure 5: Anisomycin upregulates phospho-JNK along with phospho-p38α and JNK inhibitor SP600125 can 452 
suppress anisomycin induced p38α activation  453 
 454 
Relative protein level expression of 122102, 130107, 130227, 130429 and 160915 under high (100 µM) and low (0.1 455 
µM) dose anisomycin probed for phospho-p38α/p38α, phospho-JNK/JNK, phospho-ERK/ ERK and phospho-MEK/ 456 
with hsp90 as loading control.  457 
 458 
Figure 6: p38 inhibitor-SB203580 and JNK inhibitor-SP600125 can suppress anisomycin induced p38α 459 
activation  460 
 461 
Relative protein level expression of 122102, 130107, 130227, 130429 and 160915 under low (0.1 uM) dose anisomycin 462 




anisomycin and SP600125 in 122102, 130227 and 130429 while phospho-p38α levels were reduced when co-treated 464 
with anisomycin and SB203580 in 122102,130107, 130227, 130429 and 160915. 130107 and 160915 had higher 465 
expression of phospho-p38α when co-treated with anisomycin and SP600125. On the right: Fold expression of p38α 466 
and phospho-p38α normalized to hsp90.  467 
 468 
Supplementary Figure 1:  Information on patient derived melanoma cell lines 469 
 470 
Supplementary Figure 2:  Genes with CNV gains and losses of short and long survivors with more than 80 % homology 471 
to Danio rerio genome. 472 
 473 
Supplementary Figure 3:  Dose-response matrix of synergistic effects of anisomycin and trametinib. 474 
 475 
Supplementary Figure 4: Relative protein level expression of 122102, 130107, 130227, 130429 and 160915 under low 476 
(0.1 uM) dose anisomycin at 30 minutes and 24 hours probed for phospho-ERK/ERK, phospho-p38α/p38α, phospho-477 
MEK/MEK and phospho-JNK/JNK with hsp90 as loading control. Phospho- ERK, phospho-p38 and phospho-JNK 478 
expression is reduced within 24 hours of anisomycin treatment in comparison to 30 minutes post treatment. Phospho-479 
MEK and total p38, ERK, JNK, MEK levels remain unchanged. 480 
 481 
Supplementary Figure 5:  Tumor sections of Tg(mitfa:NRASQ61K);mitfaw2;tp53zdf1 and 482 
Tg(mitfa:p38);Tg(mitfa:NRASQ61K);mitfaw2;tp53zdf1 showing spindle shaped nuclei in the latter. 483 
 484 
Supplementary Figure 6: Heatmap of RNA expression of MAPK14 with RASA1, RASA2, NF1 and SPRED1 in 485 
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